JiMu Biological Suprachoroidal Injection Therapy ARVN001 Obtains Exclusive Rights and Interests in Ten ASEAN Countries and India

Shanghai, China, August 15, 2021-Arctic Vision (hereinafter referred to as "Jimu" or "Jimu"), which focuses on innovative ophthalmic therapies, announced that it has partnered with Clearside Biomedical, Inc.

ARVN001 is a patented suspension of the glucocorticoid triamcinolone acetonide, which can be administered to the suprachoroidal space (SCS®) through the patented suprachoroidal microinjector (SCS Microinjector®).

Dr.

ARVN001 is a patented suspension of the glucocorticoid triamcinolone acetonide for suprachoroidal injection and is being developed for the treatment of uveitis macular edema (UME)

In March 2020, Jimu Biotech obtained the development and commercialization rights of XIPERE™ in Greater China (Mainland China, Hong Kong, Macau and Taiwan) and South Korea, with the project code ARVN001.

ARVN001 has not yet been approved for marketing globally, and the US New Drug Marketing Application (NDA) was accepted by the FDA in May 2021

About uveitis macular edema (UME)

Uveitis is a group of highly blinding ocular inflammatory diseases involving the uvea

About JiMu Bio

JiMu Bio is a biotechnology company headquartered in China, focusing on innovative ophthalmic therapies, with a series of breakthrough ophthalmic treatment technology product portfolios covering from the early detection stage to the commercialization stage

About Clearside Biomedical

Clearside Biomedical, Inc.

JiMu Bio Media Contact:

communications@arcticvision.